CRISPR Therapeutics Earnings Estimate

CRSP
 Stock
  

USD 66.15  0.75  1.12%   

Many public companies, such as CRISPR Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing CRISPR Therapeutics' earnings estimates, investors can diagnose different trends across CRISPR Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes.
CRISPR Therapeutics is projected to generate 5.0 in earnings per share on the 31st of December 2021. CRISPR Therapeutics earnings estimates module stress-tests analyst consensus about projected CRISPR Therapeutics AG EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Continue to Trending Equities.
  
Refresh
As of 28th of June 2022, Gross Profit is likely to grow to about 987.2 M. Also, Profit Margin is likely to grow to 0.51

CRISPR Therapeutics Earnings Estimation Breakdown

Calculation of earning per share of CRISPR Therapeutics is based on official Zacks consensus of 7 analysts regarding CRISPR Therapeutics future annual earnings. Given the historical accuracy of 24.53%, the future earnings per share of CRISPR Therapeutics is estimated to be 5.0 with the lowest and highest values of 4.76 and 5.29, respectively. Please note that this consensus of annual earnings estimates for CRISPR Therapeutics AG is an estimate of EPS before non-recurring items and including employee stock options expenses
  Current EPS 3.86
4.76
Lowest
Expected EPS 5.0
5.29
Highest

CRISPR Therapeutics Earnings Projection Consensus

Suppose the current estimates of CRISPR Therapeutics' value are higher than the current market price of the CRISPR Therapeutics stock. In this case, investors may conclude that CRISPR Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and CRISPR Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
Number of AnalystsHistorical AccuracyCurrent EPSEPS Estimate for 31st of December 2021

7

24.53%

3.86

5.0

CRISPR Therapeutics Earnings History

Earnings estimate consensus by CRISPR Therapeutics analysts from Wall Street is used by the market to judge CRISPR Therapeutics' stock performance. The investors also use these earnings estimates to evaluate and project the stock performance into the future in order to make their investment decisions. However, we recommend analyzing not only CRISPR Therapeutics' upcoming profit reports and earnings-per-share forecasts but also compare them to our different valuation methods.

CRISPR Therapeutics Quarterly Earnings Before Interest Taxes and Depreciation Amortization EBITDA

(169.57 Million)

Share
CRISPR Therapeutics Earning Before Interest and Taxes EBIT is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Earning Before Interest and Taxes EBIT of 379.53 Million. As of 28th of June 2022, Earnings per Basic Share is likely to grow to 5.36, while Accumulated Retained Earnings Deficit are likely to drop (211.4 M). As of 28th of June 2022, Issuance Purchase of Equity Shares is likely to grow to about 284.5 M, while Weighted Average Shares is likely to drop about 62.1 M.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of CRISPR Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of CRISPR Therapeutics in the context of predictive analytics.
Hype
Prediction
LowEstimated ValueHigh
66.9066.9066.90
Details
Intrinsic
Valuation
LowReal ValueHigh
60.2191.8191.81
Details
16 Analysts
Consensus
LowTarget PriceHigh
100.00160.69220.00
Details
Please note, it is not enough to conduct a financial or market analysis of a single entity such as CRISPR Therapeutics. Your research has to be compared to or analyzed against CRISPR Therapeutics' peers to derive any actionable benefits. When done correctly, CRISPR Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in CRISPR Therapeutics.
Note that many institutional investors and large investment bankers can move markets due to the volume of CRISPR assets they manage. They also follow analysts to some degree and often drive overall investor sentiments towards CRISPR Therapeutics. With so many stockholders watching consensus numbers, the difference between actual and projected earnings is one of the most critical factors driving CRISPR stock price in the short term.

CRISPR Therapeutics Earnings per Share Projection vs Actual

Actual Earning per Share of CRISPR Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering CRISPR Therapeutics AG predict the company's earnings will be in the future. The higher the earnings per share of CRISPR Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.

CRISPR Therapeutics Estimated Earnings per Share

For an investor who is primarily interested in generating an income out of investing in entities such as CRISPR Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of CRISPR Therapeutics should always be considered in relation to other companies to make a more educated investment decision.

CRISPR Quarterly Analyst Estimates and Surprise Metrics

Earnings surprises can significantly impact CRISPR Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-05-09
2022-03-31-1.94-2.32-0.3819 
2022-02-15
2021-12-31-1.77-1.84-0.07
2021-11-03
2021-09-30-1.7633-1.670.0933
2021-07-29
2021-06-303.11999.446.3201202 
2021-04-27
2021-03-31-1.4727-1.51-0.0373
2021-02-16
2020-12-31-1.2756-1.52-0.244419 
2020-10-28
2020-09-30-1.1875-1.32-0.132511 
2020-07-27
2020-06-30-0.9876-1.3-0.312431 
2020-04-28
2020-03-31-1.0429-1.15-0.107110 
2020-02-12
2019-12-310.05430.510.4557839 
2019-10-28
2019-09-301.79332.40.606733 
2019-07-29
2019-06-30-0.8955-1.01-0.114512 
2019-04-29
2019-03-31-0.8987-0.93-0.0313
2019-02-25
2018-12-31-0.7762-0.92-0.143818 
2018-11-07
2018-09-30-0.7423-1.07-0.327744 
2018-08-07
2018-06-30-0.6405-0.82-0.179528 
2018-05-08
2018-03-31-0.6701-0.620.0501
2018-03-08
2017-12-31-0.66740.00340.6708100 
2017-11-08
2017-09-30-0.6007-0.62-0.0193
2017-08-10
2017-06-30-0.6177-0.560.0577
2017-05-11
2017-03-31-0.648-0.540.10816 
2017-03-10
2016-12-31-0.4854-0.62-0.134627 
2016-11-22
2016-09-30-0.38-0.3690.011

About CRISPR Therapeutics Earnings Estimate

The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of CRISPR Therapeutics earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current CRISPR Therapeutics estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as CRISPR Therapeutics fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.
Last ReportedProjected for 2022
Accumulated Retained Earnings Deficit-195.9 M-211.4 M
Earning Before Interest and Taxes EBIT379.5 M409.5 M
Earnings per Basic Share 4.97  5.36 
Earnings per Diluted Share 4.70  5.07 
Price to Earnings Ratio 15.25  16.45 
Earnings Before Interest Taxes and Depreciation Amortization EBITDA397.5 M428.9 M
Earnings before Tax379.5 M409.5 M
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland. CRISPR Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 473 people.

CRISPR Therapeutics Investors Sentiment

The influence of CRISPR Therapeutics' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in CRISPR. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards CRISPR Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, CRISPR Therapeutics' short interest history, or implied volatility extrapolated from CRISPR Therapeutics options trading.

Current Sentiment - CRSP

CRISPR Therapeutics Investor Sentiment

Most of Macroaxis users are currently bullish on CRISPR Therapeutics AG. What is your opinion about investing in CRISPR Therapeutics AG? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish

Pair Trading with CRISPR Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CRISPR Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CRISPR Therapeutics will appreciate offsetting losses from the drop in the long position's value.

CRISPR Therapeutics Pair Correlation

Correlation Analysis For Direct Indexing and Tax-loss Harvesting

The ability to find closely correlated positions to CRISPR Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CRISPR Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CRISPR Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CRISPR Therapeutics AG to buy it.
The correlation of CRISPR Therapeutics is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CRISPR Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CRISPR Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CRISPR Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Trending Equities. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.